EUVIMEDEUVIMED entdecken
Open Access

Impact of Posttreatment SPECT/CT on Patient Management During 177 Lu-PSMA-617 Radiopharmaceutical Therapy

Surekha Yadav, Blair Lowery, Abuzar Moradi Tuchayi, Fei Jiang, Rachelle Saelee, Rahul R Aggarwal, Roxanna Juarez, Robert R Flavell, Thomas A Hope

Journal of Nuclear Medicine · 2024-09 · 65 (9) · 1395-1401

DOI: 10.2967/jnumed.124.267955 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 08.08.2024. Verfasst von Surekha Yadav und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Single Photon Emission Computed Tomography Computed Tomography, Lutetium, Dipeptides. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

177Lu can be imaged after administration using SPECT/CT. Most work to date has focused on using posttreatment imaging to measure normal organ and tumor dose. We aimed to assess the impact of posttreatment SPECT/CT on the management of patients undergoing 177Lu-prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy (RPT).

Methods

In this retrospective study, 122 patients underwent PSMA RPT with subsequent SPECT/CT 24 h after treatment. We determined a qualitative response at each cycle and reviewed patient charts to assess the impact that posttreatment SPECT/CT had on patient management. Changes in patient management were classified as changes on the basis of progression and response, and specific cycles when they occurred were noted. Miscellaneous changes in patient management were also evaluated.

Results

Among the 122 consecutive patients examined, 42%-56% exhibited stable disease, whereas 19%-39% of patients exhibited response on visual assessment across treatment cycles. In total, 49% (n = 60) of patients experienced changes in management, of which 57% (n = 34) were due to progression, 40% (n = 24) were due to response, and 3% (n = 2) were due to miscellaneous changes. Changes due to disease progression were observed mostly after cycles 2 and 4. Changes due to response to RPT occurred mostly after cycles 3 and 4.

Conclusion

At our center, 49% of patients experienced changes in management based on posttreatment SPECT/CT, and most of these changes occurred at cycles 2 and 4. Integrating posttreatment SPECT/CT into routine PSMA RPT protocols can aid in patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsSingle Photon Emission Computed Tomography Computed TomographyLutetiumDipeptidesHumansMaleRetrospective StudiesAgedMiddle AgedTreatment OutcomeHeterocyclic Compounds, 1-RingProstatic NeoplasmsAged, 80 and overProstate-Specific Antigen

Stichwörter der Autor:innen

177Lu-PSMA-617metastatic castration-resistant prostate cancerposttreatment SPECT/CTradiopharmaceutical therapy

Substanzen

RadiopharmaceuticalsLutetiumDipeptidesPluvictoHeterocyclic Compounds, 1-RingProstate-Specific Antigen

Autor:innen und Institutionen

  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California.
  • Division of Medical Oncology, Department of Medicine, University of California San Francisco, San Francisco, California.
  • Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California; and.
  • Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California; thomas.hope@ucsf.edu.
  • Department of Radiology, San Francisco VA Medical Center, San Francisco, California.

Förderung

  • NCI NIH HHS

Zitieren

APA

Yadav, S., Lowery, B., Tuchayi, A. M., Jiang, F., Saelee, R., Aggarwal, R. R., Juarez, R., Flavell, R. R., & Hope, T. A. (2024). Impact of Posttreatment SPECT/CT on Patient Management During 177 Lu-PSMA-617 Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 65(9), 1395-1401. https://doi.org/10.2967/jnumed.124.267955

Vancouver

Yadav S, Lowery B, Tuchayi AM, Jiang F, Saelee R, Aggarwal RR, et al. Impact of Posttreatment SPECT/CT on Patient Management During 177 Lu-PSMA-617 Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 2024;65(9):1395-1401. doi:10.2967/jnumed.124.267955

BibTeX
@article{Yadav2024,
  author = {Yadav, Surekha and Lowery, Blair and Tuchayi, Abuzar Moradi and Jiang, Fei and Saelee, Rachelle and Aggarwal, Rahul R and Juarez, Roxanna and Flavell, Robert R and Hope, Thomas A},
  title = {Impact of Posttreatment SPECT/CT on Patient Management During 177 Lu-PSMA-617 Radiopharmaceutical Therapy},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  volume = {65},
  number = {9},
  pages = {1395--1401},
  doi = {10.2967/jnumed.124.267955}
}
Kostenlos starten →